An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer

Mei-Ying Liao; Jun-Kai Lai; Mark Yen-Ping Kuo; Ruei-Min Lu; Cheng-Wei Lin; Ping-Chang Cheng; Kang-Hao Liang; Han-Chung Wu

doi:10.18632/oncotarget.4453

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer

Mei-Ying Liao, Jun-Kai Lai, Mark Yen-Ping Kuo, Ruei-Min Lu, Cheng-Wei Lin, Ping-Chang Cheng, Kang-Hao Liang and Han-Chung Wu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:24947-24968. https://doi.org/10.18632/oncotarget.4453

Metrics: PDF 2968 views | HTML 5432 views | ?

Abstract

Mei-Ying Liao1,2,*, Jun-Kai Lai1,*, Mark Yen-Ping Kuo2, Ruei-Min Lu1, Cheng-Wei Lin1, Ping-Chang Cheng1, Kang-Hao Liang1, Han-Chung Wu1,3

1Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan

2Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan

3Genomics Research Center, Academia Sinica, Taipei, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Han-Chung Wu, e-mail: [email protected]

Keywords: colorectal carcinoma, EpCAM, therapeutic antibody, targeting imaging, cancer therapy

Received: March 12, 2015 Accepted: July 24, 2015 Published: August 06, 2015

ABSTRACT

Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4453

Publication Alerts

Research Papers:

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer

Abstract